Page 403 - Read Online

Pearce et al. Neuroimmunol Neuroinflammation 2018;5:47 I http://dx.doi.org/10.20517/2347-8659.2018.46 Page 15 of 16

37. Vetter M, Hofer MJ, Roth E, Pircher HP, Pagenstecher A. Intracerebral interleukin 12 induces glioma rejection in the brain
predominantly by CD8+ T cells and independently of interferon-gamma. J Neuropathol Exp Neurol 2009;68:525-34.
38. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, et al. Autonomous growth and increased cytotoxicity of natural killer cells
expressing membrane-bound interleukin-15. Blood 2014;124:1081-8.
39. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T-cells by alphaPD-L1 blockade.
Proc Natl Acad Sci U S A 2008;105:15016-21.
40. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family
member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
41. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, et al. Tissue expression of PD-L1 mediates peripheral T-cell tolerance. J Exp Med
2006;203:883-95.
42. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009;229:12-26.
43. Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, et al. PD-L1 on tumor cells is sufficient for immune evasion in
immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 2017;214:895-904.
44. Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, et al. Clinical and immunologic correlates of response to PD-1 blockade in
a patient with metastatic renal medullary carcinoma. J Immunother Cancer 2017;5:1.
45. Beckermann KE, Johnson DB, Sosman JA. PD-1/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol 2017;13:77-84.
46. Allen PB, Gordon LI. PD-1 blockade in Hodgkin’s lymphoma: learning new tricks from an old teacher. Expert Rev Hematol
2016;9:939-49.
47. Garon EB. Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol 2015; doi: 10.1053/
j.seminoncol.2015.09.019.
48. Robert C, Schachter J, Long GV, Arance A, Grob JJ, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med
2015;372:2521-32.
49. Sonpavde G. PD-1 and PD-L1 inhibitors as salvage therapy for urothelial carcinoma. N Engl J Med 2017;376:1073-4.
50. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011;17:6958-62.
51. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, et al. Elimination of residual metastatic prostate cancer after surgery and
adjunctive cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999;96:15074-9.
52. Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, et al. Induction of T-cell immunity overcomes complete resistance to PD-1
and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 2015;3:399-411.
53. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, et al. Glioblastoma eradication following immune checkpoint blockade in an
orthotopic, immunocompetent model. Cancer Immunol Res 2016;4:124-35.
54. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med
2013;369:122-33.
55. Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, et al. CD200 in CNS tumor-induced immunosuppression: the role for CD200
pathway blockade in targeted immunotherapy. J Immunother Cancer 2014;2:46.
56. Olin M, Ampudia-Mesias E, Xiong Z, Pluhar E, Moertel C. IMMU-11. Targeting the CD200 checkpoint blockade: a new direction for
immunotherapy. Neuro Oncol 2017;19:vi114-5.
57. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in
mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343-9.
58. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade
yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 2014; doi: 10.1371/
journal.pone.0101764.
59. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, et al. Durable therapeutic efficacy utilizing combinatorial blockade
against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014;20:5290-301.
60. Translational Lung Cancer Research. Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. Available from:
http://tlcr.amegroups.com/article/view/15648/12897. [Last accessed on 26 Oct 2018]
61. Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res
2017;5:12.
62. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
63. Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol
2016;18:195-205.
64. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, et al. Molecular drivers of the non-T Cell-inflamed tumor microenvironment in
urothelial bladder cancer. Cancer Immunol Res 2016;4:563-8.
65. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive
T cell therapy. Cancer Cell 2017;31:711-23.
66. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, et al. Analysis of 100,000 human cancer genomes reveals the landscape of
tumor mutational burden. Genome Medicine 2017;9:34.
67. Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, et al. T-cell exhaustion signatures vary with tumor type and are
severe in glioblastoma. Clin Cancer Res 2018;24:4175-86.
68. Nakashima H, Alayo QA, Penaloza-MacMaster P, Freeman GJ, Kuchroo VK, et al. Modeling tumor immunity of mouse glioblastoma
by exhausted CD8+ T-cells. Sci Rep 2018;8:208.
69. Wang M, Yao LC, Cheng M, Cai D, Martinek J, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer
immunotherapy. FASEB J 2018;32:1537-49.
70. Razavi SM, Lee KE, Jin BE, Aujla PS, Gholamin S, et al. Immune evasion strategies of glioblastoma. Front Surg 2016;3:11.